CYP19A1 and breast carcinoma: It has been demonstrated to be efficacious in combination with endocrine therapy (eg, anti‐estrogen and aromatase inhibitors) against estrogen receptor (ER)‐positive (ER+) and HER2‐negative (HER2−) breast cancer.4